Immunic CEO discusses MS focus, upcoming Phase 3 trial readouts - ICYMI

Core Insights - Immunic Inc is experiencing strong momentum in its late-stage clinical programs, particularly with its lead asset vidofludimus calcium, which is currently in the fully enrolled ENSURE Phase 3 trials for multiple sclerosis, expected to report data by the end of 2026 [1][5][7] - The company is also making progress in its gastrointestinal program, IMU-856, which has shown promising data in celiac disease and GLP-1 upregulation, indicating potential for further development and partnerships [2][6] Conference Insights - The atmosphere at BIO-Europe 2025 was described as exciting and energetic, with significant international attendance, highlighting its importance as a networking platform for investors, business development professionals, and scientists [3][4] - The conference provided Immunic with valuable exposure to European investors and companies, complementing its existing networking efforts in the US [4] Clinical Program Feedback - Immunic received strong interest in its Phase 3 ENSURE studies for multiple sclerosis, which are seen as a unique growth opportunity in a multi-billion market [5][6] - The GI program, IMU-856, also garnered interest due to its proof-of-concept data in celiac disease and the upregulation of GLP-1, presenting an intriguing opportunity for future development [6] Strategic Outlook - The company aims to bring vidofludimus calcium to market and is focused on the upcoming Phase 3 data readouts next year, while also seeking to advance IMU-856 through clinical trials and potential partnerships [7]